Sign In
Buy AGE
$11.10
+0 (+0%)
At Close: Jun 25, 2024
NEW STUDY REVEALS HOW RETIREMENT SAVERS' INVESTMENT PREFERENCES CHANGE WITH AGE
10:30am, Tuesday, 29'th Jul 2025
T. Rowe Price, in collaboration with MIT Sloan and Stanford, finds that personalized retirement solutions may be most effective for older investors BALTIMORE , July 29, 2025 /PRNewswire/ -- T. Rowe Pr
Avis de convocation aux AGE et AGO du 28 mars 2025
03:00am, Thursday, 13'th Mar 2025
Le Président
DiagnaMed Expands with Drug and Clinical Research AI Platform
08:00am, Wednesday, 21'st Aug 2024
Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for neurol
Bitcoin dominance surges as crypto markets show signs of consolidation
07:17am, Monday, 20'th May 2024
Bitcoin (BCT) traders had nothing to write home about over the weekend trading session. The world’s largest cryptocurrency stayed flat against the US dollar on Saturday before falling around one per
QVC DEFINES A NEW AGE OF POSSIBILITY CHAMPIONING WOMEN 50 AND OVER TO LIVE THEIR BEST LIVES
12:55pm, Tuesday, 16'th Apr 2024
The shopping entertainment destination introduces its first-ever Quintessential 50 (Q50) comprised of 50 authentic and inspiring female celebrities, activists, business leaders and lifestyle experts w
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
05:04pm, Tuesday, 26'th Mar 2024
HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson'
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
05:27pm, Friday, 22'nd Mar 2024
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AgeX Thera
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
04:05pm, Tuesday, 14'th Nov 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AgeX Thera
Shareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with Serina
03:45pm, Wednesday, 30'th Aug 2023
MILWAUKEE , Aug. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating AgeX (NYSE American: AGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Serina. Clic
Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX
10:22am, Wednesday, 30'th Aug 2023
Privately-owned Serina Therapeutics Inc is being merged into AgeX Therapeutics (NYSE:AGE) in a move that will reboot the Nasdaq ‘human longevity' stock, into an immunology and gene therapy firm seek
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
07:00am, Wednesday, 30'th Aug 2023
HUNTSVILLE, Ala. & ALAMEDA, Calif.--(BUSINESS WIRE)--Serina Therapeutics, Inc. (“Serina”), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatme
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
04:05pm, Monday, 14'th Aug 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
06:28pm, Monday, 24'th Jul 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24,
